Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

19
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
19
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

18
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

37
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
37
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

122
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
122
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

863
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
863

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarkers, association, and prediction in cancer-associated thrombosis and bleeding.

European heart journal·2026
Same author

Venous Thromboembolism Prophylaxis and Postoperative Outcomes in Persons with Bleeding Disorders Undergoing Major Surgery: A Canadian Pilot Feasibility Study.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

The association between patient preferred language and end-of-life outcomes of home care patients who died from a cancer in Ontario, Canada - A retrospective cohort study.

PloS one·2026
Same author

Time-to-start of anticoagulant therapy and mortality in pulmonary embolism.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Effect of PCC on Thrombin Generation in Patients on FXaI with Bleeding or Needing Urgent Surgery (GAUGE).

Blood advances·2026
Same author

Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Related Experiment Video

Updated: Aug 30, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.6K

Thrombosis and bleeding in hematological malignancy.

Tzu-Fei Wang1, Avi Leader2, Kristen M Sanfilippo3

  • 1Department of Medicine, University of Ottawa, The Ottawa Hospital, Ottawa Hospital Research Institute, Ottawa, Canada.

Best Practice & Research. Clinical Haematology
|August 27, 2022
PubMed
Summary
This summary is machine-generated.

Patients with hematological malignancies face high risks of venous (VTE) and arterial (ATE) thromboemboli. This review examines VTE/ATE risk, prediction, and treatment, balancing efficacy with bleeding risks in this population.

Keywords:
Arterial thromboembolismBleedingCancerHematological malignancyRisk predictionVenous thromboembolism

More Related Videos

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

19.9K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

Related Experiment Videos

Last Updated: Aug 30, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.6K
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

19.9K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K

Area of Science:

  • Hematology
  • Oncology
  • Cardiovascular Medicine

Background:

  • Thromboembolism, including venous (VTE) and arterial (ATE) events, significantly contributes to morbidity and mortality in cancer patients.
  • Patients with hematological malignancies exhibit a particularly elevated risk for both VTE and ATE.
  • Existing risk prediction models and treatment guidelines for VTE are often derived from studies predominantly featuring solid tumors.

Purpose of the Study:

  • To review the current evidence on the risk and prediction of VTE and ATE in patients with hematological malignancies.
  • To discuss the challenges and considerations in treating thromboembolic events in this patient group, balancing therapeutic benefits against bleeding risks.
  • To provide insights into managing thromboembolic and bleeding complications in hematological malignancy patients.

Main Methods:

  • Comprehensive literature review of studies focusing on thromboembolism and bleeding in hematological malignancies.
  • Analysis of risk factors and predictive models for VTE and ATE in this specific patient population.
  • Evaluation of current treatment strategies for VTE and ATE, considering anticoagulant and antiplatelet therapies.

Main Results:

  • Hematological malignancy patients have a high incidence of both VTE and ATE, influenced by patient- and disease-specific factors.
  • Risk stratification and prediction models are crucial for identifying high-risk individuals within this cohort.
  • Treatment decisions require careful consideration of the competing risks of thromboembolism and bleeding.

Conclusions:

  • Understanding and predicting VTE and ATE risk is critical for managing patients with hematological malignancies.
  • Tailored treatment approaches are necessary to optimize outcomes, minimizing both thromboembolic events and anticoagulant-related bleeding.
  • Further research is warranted to refine risk prediction and treatment strategies for thromboembolism in hematological malignancies.